Nidda German Topco

Company

Nidda German Topco develops one asset, in human trials (Lecigon in advanced Parkinson disease). Mostly small molecule acting on Ddc and COMT.

1
Asset
Furthest stage: Human trials; 0
Trials: 0
Signals

Pipeline

1

Lecigon
Continuous intestinal delivery of levodopa, carbidopa, and entacapone to manage motor fluctuations.
Human trials, Small molecule, Ddc, COMT, advanced Parkinson disease

Full company profiles: pipeline, trials, funding and people.

Subsidiaries

1

Britannia Pharmaceuticals
1 asset

In the full profile

Evidence behind the mechanisms2
Similar companies1